Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharmaceuticals
Epic: BNO
News: Latest news
Web Site: Bionomics
Other Articles: 07-06-201026-05-201006-05-2010 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday July 29, 09:30Specialist Energy Group Lays Out a Compelling Blueprint for Growth

After a difficult start to life as a stock market listed company, the company now stands at the threshold of a much brighter future. Legacy issues have been dealt with and the turnaround programme initiated by CEO Ewan Lloyd-Baker is gaining traction.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday July 28, 11:30Silver Lake Resources boosts high grade gold resource by 70% to 2.5m ounces

Silver Lake Resources has added over 1 million ounces of gold to its resource inventory during the year after mining 66,700 ounces and expects further encouraging results at its  Mount Monger and Murchison projects.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive CN ▼

Thursday July 15, 02:10Henan Yuguang Lead & Gold investment in Kimberley Metals receives all clear from FIRB

Kimberley Metals (ASX: KBL) has reported that on 12 July the Australian Government Foreign Investment Review Board (FIRB) had no objections to Henan Yuguang Lead & Gold Co. Ltd's [...]

FULL ARTICLE ►
Bionomics

Bionomics

Bionomics is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system. Through application of its proprietary technology platforms, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy.

CLICK HERE FOR FULL ANLAYSIS OF BIONOMICS
Tuesday, March 16, 2010

Bionomics to present at Ultimate Healthcare & Biotechnology Event, March 24

Leading European investment house Edison Investment Research has provided a new valuation of Bionomics (ASX: BNO) at 55 cents per share. 

Current BNO share price is 31 cents.

This was based mainly on "an assessment of the potential economic reward and timelines associated with successful development of BNO's BNC105 compound."

The valuation largely excluded the value of milestone payments, including those potentially receivable from Merck Serono in relation to the Kv1.3 program or from potential licensing deals for BNC105 and BNC210.

The Edison report also contained an overview of recent cancer licensing deals to provide an indication of the potential of a BNC105 licensing deal.

Edison arrived at a value of A$175m for the company based on a risk-adjusted net present value of key programs for BNO.

“VDAs are considered to have significant commercial potential in the treatment of cancer, especially as their mechanism makes them likely to be applicable to a wide variety of solid tumour types”.

“BNC105 is likely to be, in our view, a very attractive asset”. A partnership for BNC105 could generate substantial economic return.”

The Edison report also contained an overview of recent cancer licensing deals to provide an indication of the potential of a BNC105 licensing deal.

Edison Reseach concluded: "This valuation leaves considerable “upside” [for the BNO share price] as Bionomics achieves clinical milestones, as well as commercial milestones."

AddThis Feed Button
Register here to be notified of future Bionomics articles.

Other Bionomics articles


Other Bionomics news

More news ►

Investors interested in Bionomics recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.